Can You Prescribe Lorazepam and Temazepam with Escitalopram Together?
Yes, lorazepam and temazepam can be co-prescribed with escitalopram, but this requires careful monitoring for additive CNS depression and should generally be reserved for specific clinical scenarios rather than routine practice.
Clinical Context and Safety Profile
The combination of benzodiazepines (lorazepam, temazepam) with SSRIs (escitalopram) is commonly used in clinical practice, though it requires understanding of both the benefits and risks.
From FDA Drug Labeling Perspective
Temazepam's FDA label explicitly warns about additive effects on psychomotor performance with concomitant CNS depressants 1. The label states that if temazepam is combined with other drugs having CNS-depressant effects, consideration should be given to potential additive effects. However, this is a caution, not a contraindication 1.
Escitalopram's FDA label does not list benzodiazepines as contraindicated medications 2. The primary drug interaction concerns for escitalopram involve serotonergic agents (risk of serotonin syndrome) and drugs affecting coagulation 2.
Evidence from Clinical Guidelines
The 2008 American Academy of Sleep Medicine guidelines specifically acknowledge that benzodiazepines not specifically approved for insomnia (including lorazepam) "might also be considered if the duration of action is appropriate for the patient's presentation or if the patient has a comorbid condition that might benefit from these drugs" 3. This guideline explicitly discusses using sedating antidepressants in combination with benzodiazepine receptor agonists, noting that "a wealth of clinical experience with the co-administration of these drugs suggests the general safety and efficacy of this combination" 3.
The guidelines recommend that when combining medications from two different classes, this may "improve efficacy by targeting multiple sleep-wake mechanisms while minimizing the toxicity that could occur with higher doses of a single agent" 3.
Specific Clinical Scenarios Where Combination is Appropriate
1. Comorbid Anxiety and Insomnia with Depression
When a patient presents with major depressive disorder plus significant anxiety or insomnia, the combination makes clinical sense:
- Escitalopram addresses the underlying depression and anxiety (therapeutic effect takes 4-8 weeks)
- Lorazepam (for anxiety) or temazepam (for insomnia) provides immediate symptom relief during the SSRI titration period 3
2. Bridging Therapy
Short-term benzodiazepine use (typically 2-4 weeks) while waiting for escitalopram to reach therapeutic effect is a common and reasonable approach 3.
3. Treatment-Resistant Cases
The guidelines suggest combined BzRA (benzodiazepine receptor agonist) and antidepressant therapy as a fourth-line option for chronic insomnia when other treatments have failed 3.
Critical Safety Monitoring Requirements
When co-prescribing these medications, you must monitor for:
Additive CNS Depression
- Excessive sedation and daytime drowsiness
- Cognitive impairment and memory difficulties
- Psychomotor impairment affecting driving and operating machinery 3, 1
- Increased fall risk, particularly in elderly patients 1
Specific Warnings from FDA Labels
Temazepam's label warns about:
- Complex sleep behaviors (sleep-driving, sleep-eating) - risk increases with combination therapy 1
- Respiratory depression risk, especially if combined with opioids 1
- Paradoxical agitation (occurs in ~10% of benzodiazepine-treated patients) 4
Practical Prescribing Algorithm
Step 1: Assess the Clinical Indication
- Is there comorbid anxiety/insomnia requiring immediate relief?
- Has the patient failed monotherapy with escitalopram?
- Is this intended as short-term bridging therapy?
Step 2: Choose the Appropriate Benzodiazepine
- Lorazepam: For daytime anxiety (short-intermediate half-life, less likely to accumulate) 4
- Temazepam: For sleep-onset and maintenance insomnia (15-30 mg at bedtime) 5, 3
Step 3: Start with Lowest Effective Doses
- Escitalopram: 10 mg daily (standard starting dose)
- Lorazepam: 0.5-1 mg as needed (maximum 2-3 mg/day divided)
- Temazepam: 7.5-15 mg at bedtime (especially in elderly or debilitated patients) 3
Step 4: Set Clear Duration Expectations
- Plan for benzodiazepine discontinuation after 2-4 weeks once escitalopram reaches therapeutic effect
- Educate patient that benzodiazepines are temporary adjuncts, not long-term solutions 3
Step 5: Monitor Closely
- Assess every 2-4 weeks initially for effectiveness and side effects 3
- Watch for signs of tolerance, dependence, or dose escalation 3
- Monitor for excessive sedation, falls, cognitive impairment 1
Important Caveats and Contraindications
Avoid or Use Extreme Caution In:
- Elderly patients: Higher risk of falls, cognitive impairment, and paradoxical agitation 3, 4, 1
- Patients with respiratory compromise (asthma, COPD, sleep apnea) 1
- History of substance use disorders: Consider ramelteon instead of benzodiazepines 3
- Concurrent opioid use: Significantly increases respiratory depression risk 1
- Severe hepatic impairment: Requires dose reduction 3
Patient Education Requirements
Per FDA labeling, patients must be counseled about 1:
- Risk of complex sleep behaviors (sleep-driving)
- Avoiding alcohol and other CNS depressants
- Not driving until effects are known
- Risk of withdrawal symptoms with abrupt discontinuation
- Proper disposal of unused medication
Evidence Quality Considerations
The 2017 AASM guideline provides weak recommendations for both temazepam (for sleep onset and maintenance insomnia) and escitalopram is not specifically addressed for insomnia 5. However, the 2008 guidelines provide more detailed consensus-based recommendations supporting combination therapy when clinically indicated 3.
Research evidence is limited: One animal study showed differential effects of escitalopram and lorazepam on behavior 6, and anticholinergic activity studies show both escitalopram and temazepam have minimal anticholinergic effects (<5 pmol/mL) 7, reducing concern for anticholinergic burden when combined.
Bottom Line
The combination is not contraindicated and can be safely prescribed when:
- There is clear clinical indication (comorbid anxiety/insomnia with depression)
- Benzodiazepines are used short-term (2-4 weeks) as bridging therapy
- Lowest effective doses are employed
- Close monitoring for CNS depression, falls, and cognitive impairment is maintained
- Patient is educated about risks and proper use
- A clear tapering plan for the benzodiazepine is established from the outset
The key is avoiding long-term concurrent use and having a specific therapeutic rationale rather than reflexively combining these medications 3.